Gilead Wins Rights To Hep C Drug In Roche Patent Dispute
A New York arbitration panel ruled Thursday that Gilead Sciences Inc. has the rights to the groundbreaking hepatitis C drug Sovaldi in a patent licensing dispute with rival pharmaceutical giant F....To view the full article, register now.
Already a subscriber? Click here to view full article